DGAP-News: Oasmia Pharmaceutical AB: Oasmia Pharmaceutical's application for listing on Frankfurt Stock Exchange approved
(firmenpresse) - DGAP-News: Oasmia Pharmaceutical AB / Key word(s): IPO
Oasmia Pharmaceutical AB: Oasmia Pharmaceutical's application for
listing on Frankfurt Stock Exchange approved
21.01.2011 / 11:19
---------------------------------------------------------------------
Uppsala, January 21, 2011. The Swedish company Oasmia Pharmaceutical AB is
now approved for listing on the German stock market. The first day of
trading will be on Monday, January 24, 2011. The company is listed on
NASDAQ OMX Stockholm and will have a dual listing.
Oasmia Pharmaceutical AB (ISIN SE0000722365), focused on developing a new
generation of pharmaceuticals for the oncology sector, will be listed on
the General Standard at Frankfurt Stock Exchange, on Monday, 24 January
2011. This makes Oasmia the first Swedish company to be listed on the
regulated German market. Oasmia is already listed on the NASDAQ OMX
Stockholm Stock Exchange. The lead manager of the dual-listing process in
Germany is Silvia Quandt&Cie. AG together with biw Bank für Investments
und Wertpapiere AG.
- It feels exciting to be a part of one of the largest stock markets in the
world and we can now expand our business network considerably, comments
Julian Aleksov, CEO of Oasmia Pharmaceutical AB.
Solubility of drugs utilized in the oncology therapeutics market is a key
issue in the pharmaceutical industry. Oasmia is a pharmaceutical company
that develops semi-synthesized substances, primarily for anti-cancer
chemotherapy, based on an innovative molecular nanotechnology. Thanks to
the new water soluble formulation, the results in the clinical phases are
promising. Oasmia's formulation is able to improve the characteristics of
existing chemotherapeutical compounds and expand the area of their
applications.
The cytostatics market, in which Oasmia is active, represents around 50% of
the global oncology therapeutics market for human health (core business of
Oasmia). According to a recent report, this market amounted to US$ 60.6 bn
in 2010, and is estimated to have a Compound Annual Growth Rate of 10.9%
between 2008 and 2015.
The product candidate for treatment of ovarian cancer, Paclical(R), is
going through the final stage of Phase III study and is expected to be
filed in Europe during 2011 and in the US during 2012. The product
candidate Paccal(R) Vet has been submitted to the FDA and EMA for approval.
If approved, Paccal(R) Vet will be the first cytostatic for treatment of
cancer in dogs. In this regard Oasmia has entered into strategic agreements
with renowned pharmaceutical companies related to the distribution of
Paccal(R) Vet; Abbott Laboratories in the US/Canada, Orion in Europe and
Nippon Zenyaku Kogyo in Japan.
The current market capitalization of Oasmia is SEK 860 million (EUR 100
million). In November 2010, Oasmia carried out a successful capital
increase, generating EUR 25 million in new funds advised by Carnegie,
Sweden. This places the company in a good financial position for
developing its product portfolio.
About Oasmia
Oasmia Pharmaceutical AB develops a new generation of drugs within human
and veterinary oncology. The product development aims to manufacture novel
formulations based on well-established cytostatics which, in comparison
with current alternatives, show improved properties, a reduced side-effect
profile and an expanded therapeutic area. The productdevelopment is based
on in-house research within nanotechnology and company patents. The company
was registered in 1999 and is located in Uppsala, Sweden.
Information is also available at www.nasdaqomxnordic.com and www.oasmia.com
Contact Press Relation Germany:
edicto GmbH
Axel Mühlhaus, Dr. Sönke Knop
Eschersheimer Landstr. 42
60322 Frankfurt
Tel. +49 (69) 90 55 05 51
oasmia(at)edicto.de
www.edicto.de
Contact Capital Market Advisory:
Autenrieth Capital GmbH&Co. KG
Nicola R. Facciorusso,
Maximilianstrasse 35a
80539 München
+49 (171) 6 40 54 56
facciorusso(at)autenriethcapital.com
www.autenriethcapital.com
End of Corporate News
---------------------------------------------------------------------
21.01.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
109637 21.01.2011
Datum: 21.01.2011 - 11:19 Uhr
Sprache: Deutsch
News-ID 33039
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 242 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Oasmia Pharmaceutical AB: Oasmia Pharmaceutical's application for listing on Frankfurt Stock Exchange approved"
steht unter der journalistisch-redaktionellen Verantwortung von
Oasmia Pharmaceutical AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
